PCSK9 antagonists
US9175093B2 · kind B2 · utility
2Cited by
13References
11Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Apr 4, 2013 |
| Grant date | Nov 3, 2015 |
| Priority date | — |
| Expiry date | Apr 14, 2033 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides antagonizing antibodies, antigen-binding portions thereof, and aptamers that bind to proprotein convertase subtilisin kexin type 9 (PCSK9). Also provided are antibodies directed to peptides, in which the antibodies bind to PCSK9. The invention further provides a method of obtaining such antibodies and antibody-encoding nucleic acid. The invention further relates to therapeutic methods for use of these antibodies and antigen-binding portions thereof to reduce LDL-cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease, including treatment of hypercholesterolemia.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.